ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORIC vs KURA // ALTMAN Z-SCORE & DEBT/EQUITY

Oric Pharmaceuticals Inc. (NASDAQ) VS. Kura Oncology Inc. (NASDAQ) • 15-METRIC TALLY: ORIC 1 — KURA 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORIC VS. KURA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORIC KURA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -33.40% -35.00% +1.60 ORIC /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -11.99% -7.53% -4.46 KURA /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 25.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 KURA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 31.8 53.1 -21.30 KURA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $931.8M $939.4M -$7.6M KURA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORIC REV KURA REV ORIC GROSS % KURA GROSS % ORIC FCF KURA FCF
FY 2025 $0 $67.5M — — -$111.7M -$70.7M
FY 2024 $0 $53.9M — — -$113.8M $133.8M
FY 2023 $0 $0 — — -$85.7M -$124.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORIC // BETA —
KURA // BETA —